Monthly
US$200
Billed every month
Sign in to subscribeAs of 13 November 2026, for Doxycycline Hyclate Tablets, 10 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 5 holders.
Companies, stages and changes, with each record available on this page.
Listed in the US FDA Orange Book as ACTICLATE (NDA 205931, CHARTWELL RX SCIENCES LLC).
Last 90 days: Accepted: 1 application
Current coverage may be incomplete
The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.
Orange Book source export date: 2026/11/06. Version: 2026-11-06.
Showing 5 of 9 distinct brand names.
A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.
Verified official English dosage form: Tablets. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| ACTICLATE | CHARTWELL RX SCIENCES LLC | NDA 205931 · Product no. 001, 002 | TABLET | ORAL | HUMAN PRESCRIPTION DRUG | 2014/07/25 |
| VIBRA-TABS | PFIZER LABORATORIES DIV PFIZER INC | NDA 050533 · Product no. 001 | TABLET | ORAL | DISCONTINUED | Approved prior to 1982 (exact date not listed) |
| PERIOSTAT | GALDERMA LABORATORIES LP | NDA 050783 · Product no. 001 | TABLET | ORAL | DISCONTINUED | 2001/02/02 |
| LYMEPAK | CHARTWELL PHARMA NDA B2 HOLDINGS | NDA 209844 · Product no. 001 | TABLET | ORAL | DISCONTINUED | 2018/06/15 |
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| DORYX MPC | MAYNE PHARMA INTERNATIONAL PTY LTD | NDA 050795 · Product no. 007 | TABLET, DELAYED RELEASE | ORAL | HUMAN PRESCRIPTION DRUG | 2016/05/20 |
| PERIOSTAT | COLLAGENEX INC | NDA 050744 · Product no. 001 | CAPSULE | ORAL | DISCONTINUED | 1998/09/30 |
| DORYX MPC | MAYNE PHARMA INTERNATIONAL PTY LTD | NDA 050795 · Product no. 008 | TABLET, DELAYED RELEASE | ORAL | DISCONTINUED | 2016/05/20 |
Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Loaded records: 5 holders; 3 in the quality-and-efficacy consistency-evaluation category, and 2 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Guangzhou Shi Mo Xi Bio Technology Co., Ltd. romanized | Guangzhou Kang He Pharma Co., Ltd. romanized | 国药准字H20269241 | 2026/09/29 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Guangzhou Shi Mo Xi Bio Technology Co., Ltd. romanized | Guangzhou Kang He Pharma Co., Ltd. romanized | 国药准字H44022831 | 2026/09/29 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| TC Pharmaceuticals (Jiangsu) Co., Ltd | TC Pharmaceuticals (Jiangsu) Co., Ltd | 国药准字H20266127 | 2026/09/29 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Hangzhou Fu Ou Pharmaceuticals Technology Co., Ltd. romanized | Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | 国药准字H20263331 | 2026/02/02 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Hangzhou Fu Ou Pharmaceuticals Technology Co., Ltd. romanized | Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | 国药准字H20263332 | 2026/02/02 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Te Yi Pharma Group Co., Ltd. romanized | Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44021106 | 2025/02/25 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Te Yi Pharma Group Co., Ltd. romanized | Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44023645 | 2025/02/25 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | 国药准字H32021266 | 2022/03/30 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
Loaded records: 56 distinct approval numbers and 43 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Guangdong Bang Min Pharmaceutical Factory Co., Ltd. romanized | 国药准字H44022263 | See source | Category A | XJ01AAD193A001010100267 | NHSA |
| Guangdong Bi Di Pharma Co., Ltd. romanized | 国药准字H44021610 | See source | Category A | XJ01AAD193A001010100269 | NHSA |
| Guangdong Hua Nan Pharma Group Co., Ltd. romanized | 国药准字H44025005 | See source | Category A | XJ01AAD193A001010100290 | NHSA |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | 国药准字H44021882 | See source | Category A | XJ01AAD193A001010100315 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44023645 | See source | Category A | XJ01AAD193A001010100341 | NHSA |
| Guangdong Zhong Sheng Pharma Co., Ltd. romanized | 国药准字H44021455 | See source | Category A | XJ01AAD193A001010100353 | NHSA |
| Guangzhou Bai Yun Shan Guang Hua Pharmaceutical Co., Ltd. romanized | 国药准字H44020175 | See source | Category A | XJ01AAD193A001010100372 | NHSA |
| Guangzhou Kang He Pharma Co., Ltd. romanized | 国药准字H44022831 | See source | Category A | XJ01AAD193A001010100401 | NHSA |
| Li Zhu Group Li Min Pharmaceutical Factory romanized | 国药准字H44020593 | See source | Category A | XJ01AAD193A001010100454 | NHSA |
| Shanghai Shang Yao Xin Yi Pharmaceutical Factory Co., Ltd. romanized | 国药准字H31021129 | See source | Category A | XJ01AAD193A001010100818 | NHSA |
| Hui Rui Pharmaceutical Co., Ltd. romanized | 国药准字H19993983 | See source | Category A | XJ01AAD193A001010101187 | NHSA |
| Jiangsu Lian Shui Pharmaceutical Co., Ltd. romanized | 国药准字H32023940 | See source | Category A | XJ01AAD193A001010101466 | NHSA |
| Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | 国药准字H32021266 | See source | Category A | XJ01AAD193A001010101467 | NHSA |
| Jiangsu Ping Guang Pharmaceutical Co., Ltd. romanized | 国药准字H32021227 | See source | Category A | XJ01AAD193A001010101471 | NHSA |
| Jiangsu Rui Nian Qian Jin Pharmaceutical Co., Ltd. romanized | 国药准字H32020684 | See source | Category A | XJ01AAD193A001010101474 | NHSA |
| Suzhou Hong Sen Pharma Co., Ltd. romanized | 国药准字H32020364 | See source | Category A | XJ01AAD193A001010101518 | NHSA |
| De Quan Medicines (Jiangsu) Co., Ltd. romanized | 国药准字H20266127 | See source | Category A | XJ01AAD193A001010101751 | NHSA |
| Yi Chang Ren Fu Pharma Co., Ltd. romanized | 国药准字H42022002 | 0.1g | Category A | XJ01AAD193A001010102000 | NHSA |
| Chengdu Di Yi Pharmaceutical Co., Ltd. romanized | 国药准字H51022998 | See source | Category A | XJ01AAD193A001010102080 | NHSA |
| Shaanxi Xi Yue Pharmaceutical Co., Ltd. romanized | 国药准字H20064734 | 0.1g | Category A | XJ01AAD193A001010102439 | NHSA |
| Xian Di Sai Bio Pharma Co., Ltd. romanized | 国药准字H61020895 | 0.1g | Category A | XJ01AAD193A001010102470 | NHSA |
| Hebei Chang Tian Pharma Co., Ltd. romanized | 国药准字H13020640 | See source | Category A | XJ01AAD193A001010102596 | NHSA |
| Hebei Dong Feng Pharma Co., Ltd. romanized | 国药准字H13021945 | See source | Category A | XJ01AAD193A001010102605 | NHSA |
| Wan Bang De Pharmaceutical Group Co., Ltd. romanized | 国药准字H13022241 | See source | Category A | XJ01AAD193A001010102779 | NHSA |
| Da Tong Shi Li Qun Pharma Co., Ltd. romanized | 国药准字H14020498 | See source | Category A | XJ01AAD193A001010102844 | NHSA |
| An Yang Shi Hua An Pharma Co., Ltd. romanized | 国药准字H41020833 | See source | Category A | XJ01AAD193A001010102996 | NHSA |
| Shanghai An Ding Bio (Tang Yin) Pharma Co., Ltd. romanized | 国药准字H41021433 | See source | Category A | XJ01AAD193A001010103062 | NHSA |
| Topfond Pharmaceutical Co., Ltd. | 国药准字H41020347 | See source | Category A | XJ01AAD193A001010103098 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020946 | See source | Category A | XJ01AAD193A001010103139 | NHSA |
| Pu Yang Shi Hui Yuan Pharma Co., Ltd. romanized | 国药准字H41022128 | See source | Category A | XJ01AAD193A001010103182 | NHSA |
| Henan Da Xin Pharma Co., Ltd. romanized | 国药准字H41021958 | See source | Category A | XJ01AAD193A001010103225 | NHSA |
| Kai Feng Kang Nuo Pharma Co., Ltd. romanized | 国药准字H41023619 | See source | Category A | XJ01AAD193A001010103244 | NHSA |
| Jilin Wan Tong Pharma Group Mei He Pharma Co., Ltd. romanized | 国药准字H22023683 | See source | Category A | XJ01AAD193A001010103498 | NHSA |
| Haerbin Tai Hua Pharma Co., Ltd. romanized | 国药准字H19994039 | See source | Category A | XJ01AAD193A001010103673 | NHSA |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H37022402 | See source | Category A | XJ01AAD193A001010104240 | NHSA |
| Anhui Chang Jiang Pharma Co., Ltd. romanized | 国药准字H34021049 | See source | Category A | XJ01AAD193A001010104451 | NHSA |
| Fujian Sheng San Ming Tian Tai Pharmaceutical Co., Ltd. romanized | 国药准字H35020048 | See source | Category A | XJ01AAD193A001010104805 | NHSA |
| Jiangxi Qing Feng Pharma Co., Ltd. romanized | 国药准字H20143033 | See source | Category A | XJ01AAD193A001010105337 | NHSA |
| Jiangxi Xin Gan Jiang Pharma Co., Ltd. romanized | 国药准字H36020566 | See source | Category A | XJ01AAD193A001010105375 | NHSA |
| Hainan Sai Li Ke Pharma Co., Ltd. romanized | 国药准字H46020437 | See source | Category A | XJ01AAD193A001010105805 | NHSA |
| Gansu Lan Yao Pharma Co., Ltd. romanized | 国药准字H62020641 | See source | Category A | XJ01AAD193A001010105863 | NHSA |
| Gansu Cheng Ji Bio Pharma Co., Ltd. romanized | 国药准字H62020111 | 0.1g | Category A | XJ01AAD193A001010105889 | NHSA |
| Pu Yang Shi Hui Yuan Pharma Co., Ltd. romanized | 国药准字H41022128 | See source | Category A | XJ01AAD193A001010158310 | NHSA |
| Hangzhou Fu Ou Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263331 | See source | Category A | XJ01AAD193A001010184160 | NHSA |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | 国药准字H44021882 | See source | Category A | XJ01AAD193A001010200315 | NHSA |
| Guangdong Zhong Sheng Pharma Co., Ltd. romanized | 国药准字H44021455 | See source | Category A | XJ01AAD193A001010200353 | NHSA |
| De Quan Medicines (Jiangsu) Co., Ltd. romanized | 国药准字H20266127 | See source | Category A | XJ01AAD193A001010201751 | NHSA |
| Hebei Dong Feng Pharma Co., Ltd. romanized | 国药准字H13021945 | See source | Category A | XJ01AAD193A001010202605 | NHSA |
| Da Tong Shi Li Qun Pharma Co., Ltd. romanized | 国药准字H14020498 | See source | Category A | XJ01AAD193A001010202844 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020946 | See source | Category A | XJ01AAD193A001010203139 | NHSA |
| Pu Yang Shi Hui Yuan Pharma Co., Ltd. romanized | 国药准字H41022128 | See source | Category A | XJ01AAD193A001010203182 | NHSA |
| Henan Da Xin Pharma Co., Ltd. romanized | 国药准字H41021958 | See source | Category A | XJ01AAD193A001010203225 | NHSA |
| Yan Tai Lu Yin Pharma Co., Ltd. romanized | 国药准字H37022403 | See source | Category A | XJ01AAD193A001010204240 | NHSA |
| Fujian Sheng San Ming Tian Tai Pharmaceutical Co., Ltd. romanized | 国药准字H35020048 | See source | Category A | XJ01AAD193A001010204805 | NHSA |
| Gansu Cheng Ji Bio Pharma Co., Ltd. romanized | 国药准字H62020111 | 0.1g | Category A | XJ01AAD193A001010205889 | NHSA |
| Hangzhou Fu Ou Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263331 | See source | Category A | XJ01AAD193A001010284160 | NHSA |
| De Quan Medicines (Jiangsu) Co., Ltd. romanized | 国药准字H20266127 | See source | Category A | XJ01AAD193A001010301751 | NHSA |
| Hebei Dong Feng Pharma Co., Ltd. romanized | 国药准字H13021945 | See source | Category A | XJ01AAD193A001010302605 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41022186 | See source | Category A | XJ01AAD193A001010303139 | NHSA |
| Henan Da Xin Pharma Co., Ltd. romanized | 国药准字H41021958 | See source | Category A | XJ01AAD193A001010303225 | NHSA |
| De Quan Medicines (Jiangsu) Co., Ltd. romanized | 国药准字H20266127 | See source | Category A | XJ01AAD193A001010401751 | NHSA |
| Hebei Dong Feng Pharma Co., Ltd. romanized | 国药准字H13021945 | See source | Category A | XJ01AAD193A001010402605 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41022186 | See source | Category A | XJ01AAD193A001010403139 | NHSA |
| Hebei Dong Feng Pharma Co., Ltd. romanized | 国药准字H13021945 | See source | Category A | XJ01AAD193A001010502605 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020946 | See source | Category A | XJ01AAD193A001010503139 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020946 | See source | Category A | XJ01AAD193A001010603139 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020946 | See source | Category A | XJ01AAD193A001010703139 | NHSA |
| Guangdong Hua Nan Pharma Group Co., Ltd. romanized | 国药准字H44025004 | See source | Category A | XJ01AAD193A001020100290 | NHSA |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | 国药准字H44021881 | See source | Category A | XJ01AAD193A001020100315 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44021106 | See source | Category A | XJ01AAD193A001020100341 | NHSA |
| Guangzhou Bai Yun Shan Guang Hua Pharmaceutical Co., Ltd. romanized | 国药准字H44020431 | See source | Category A | XJ01AAD193A001020100372 | NHSA |
| Guangzhou Kang He Pharma Co., Ltd. romanized | 国药准字H44022831 | See source | Category A | XJ01AAD193A001020100401 | NHSA |
| Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | 国药准字H32021266 | See source | Category A | XJ01AAD193A001020101467 | NHSA |
| Chengdu Di Yi Pharmaceutical Co., Ltd. romanized | 国药准字H51022999 | See source | Category A | XJ01AAD193A001020102080 | NHSA |
| Shaanxi Xi Yue Pharmaceutical Co., Ltd. romanized | 国药准字H20064733 | 50mg | Category A | XJ01AAD193A001020102439 | NHSA |
| Topfond Pharmaceutical Co., Ltd. | 国药准字H41020868 | See source | Category A | XJ01AAD193A001020103098 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020947 | See source | Category A | XJ01AAD193A001020103139 | NHSA |
| Henan Da Xin Pharma Co., Ltd. romanized | 国药准字H41021959 | See source | Category A | XJ01AAD193A001020103225 | NHSA |
| Jiangxi Qing Feng Pharma Co., Ltd. romanized | 国药准字H20143033 | See source | Category A | XJ01AAD193A001020105337 | NHSA |
| Jiangxi Xin Gan Jiang Pharma Co., Ltd. romanized | 国药准字H36020567 | See source | Category A | XJ01AAD193A001020105375 | NHSA |
| Hangzhou Fu Ou Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263332 | See source | Category A | XJ01AAD193A001020184160 | NHSA |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | 国药准字H44021881 | See source | Category A | XJ01AAD193A001020200315 | NHSA |
| Guangzhou Kang He Pharma Co., Ltd. romanized | 国药准字H44022831 | See source | Category A | XJ01AAD193A001020200401 | NHSA |
| Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | 国药准字H32021266 | See source | Category A | XJ01AAD193A001020201467 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020947 | See source | Category A | XJ01AAD193A001020203139 | NHSA |
| Jiangxi Qing Feng Pharma Co., Ltd. romanized | 国药准字H20143033 | See source | Category A | XJ01AAD193A001020205337 | NHSA |
| Hangzhou Fu Ou Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263332 | See source | Category A | XJ01AAD193A001020284160 | NHSA |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | 国药准字H44021881 | See source | Category A | XJ01AAD193A001030100315 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44023645 | See source | Category A | XJ01AAD193A001030100341 | NHSA |
| Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | 国药准字H32021266 | See source | Category A | XJ01AAD193A001030101467 | NHSA |
| Shaanxi Xi Yue Pharmaceutical Co., Ltd. romanized | 国药准字H20064734 | 0.1g | Category A | XJ01AAD193A001030102439 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020946 | See source | Category A | XJ01AAD193A001030103139 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44023645 | See source | Category A | XJ01AAD193A001030200341 | NHSA |
| Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | 国药准字H32021266 | See source | Category A | XJ01AAD193A001030201467 | NHSA |
| Shaanxi Xi Yue Pharmaceutical Co., Ltd. romanized | 国药准字H20064734 | 0.1g | Category A | XJ01AAD193A001030202439 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020946 | See source | Category A | XJ01AAD193A001030203139 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44023645 | See source | Category A | XJ01AAD193A001030300341 | NHSA |
| Shaanxi Xi Yue Pharmaceutical Co., Ltd. romanized | 国药准字H20064734 | 0.1g | Category A | XJ01AAD193A001030302439 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41022186 | See source | Category A | XJ01AAD193A001030303139 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44023645 | See source | Category A | XJ01AAD193A001030400341 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44023645 | See source | Category A | XJ01AAD193A001030500341 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44023645 | See source | Category A | XJ01AAD193A001030600341 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44023645 | See source | Category A | XJ01AAD193A001030700341 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44021106 | See source | Category A | XJ01AAD193A001040100341 | NHSA |
| Shaanxi Xi Yue Pharmaceutical Co., Ltd. romanized | 国药准字H20064734 | 0.1g | Category A | XJ01AAD193A001040102439 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41020947 | See source | Category A | XJ01AAD193A001040103139 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44021106 | See source | Category A | XJ01AAD193A001040200341 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44021106 | See source | Category A | XJ01AAD193A001040300341 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44021106 | See source | Category A | XJ01AAD193A001040400341 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44021106 | See source | Category A | XJ01AAD193A001040500341 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44021106 | See source | Category A | XJ01AAD193A001040600341 | NHSA |
| Te Yi Pharma Group Co., Ltd. romanized | 国药准字H44021106 | See source | Category A | XJ01AAD193A001040700341 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Loaded records: 10 filings and 8 distinct first applicants.
Generic 8 · Supplement 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | CYHS2502969 | Generic | 2025/08/14 | Not stated by source | CDE |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | CYHS2502968 | Generic | 2025/08/14 | Not stated by source | CDE |
| Fujian Hai Xi Xin Yao Chuang Zhi Co., Ltd. romanized | CYHS2601459 | Generic | 2026/06/22 | Not stated by source | CDE |
| Anhui Jie Xi Pharmaceuticals Co., Ltd. romanized | CYHS2601168 | Generic | 2026/05/18 | Not stated by source | CDE |
| Anhui Jie Xi Pharmaceuticals Co., Ltd. romanized | CYHS2601167 | Generic | 2026/05/18 | Not stated by source | CDE |
| Hebei Dong Feng Pharma Co., Ltd. romanized | CYHB2650110 | Supplement | 2026/04/30 | Not stated by source | CDE |
| Zhejiang Yi Han Pharmaceutical Co., Ltd. romanized | CYHS2504388 | Generic | 2025/12/25 | Not stated by source | CDE |
| Hua Zhong Pharma Co., Ltd. romanized | CYHS2503937 | Generic | 2025/11/13 | Not stated by source | CDE |
| Chengdu Shuo De Pharma Co., Ltd. romanized | CYHS2503512 | Generic | 2025/09/25 | Not stated by source | CDE |
| Jiangxi Ke Rui Pharma Co., Ltd. romanized; Jiangxi Qing Feng Pharma Co., Ltd. romanized | CYHB2602003 | Supplement | 2026/11/04 | Not stated by source | CDE |
Loaded records: 3 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Fujian Hai Xi Xin Yao Chuang Zhi Co., Ltd. romanized | CYHS2601459 | Generic | 2026/06/22 | Not stated by source | CDE |
| Anhui Jie Xi Pharmaceuticals Co., Ltd. romanized | CYHS2601168 | Generic | 2026/05/18 | Not stated by source | CDE |
| Anhui Jie Xi Pharmaceuticals Co., Ltd. romanized | CYHS2601167 | Generic | 2026/05/18 | Not stated by source | CDE |
Non-component matches: 12 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 盐酸多西环素 · No verified English name | Nan Tong Chang You Pharma Technology Co., Ltd. romanized | Y20240001089 | A | Exact ingredient | 2026/08/15 | CDE |
| 多西环素 · No verified English name | Nan Tong Chang You Pharma Technology Co., Ltd. romanized | Y20240000584 | I | Salt-normalized ingredient | 2024/08/21 | CDE |
| 盐酸多西环素 · No verified English name | HOVIONE PHARMASCIENCE LIMITED | Y20220000451 | A | Exact ingredient | 2026/05/20 | CDE |
| 盐酸多西环素 · No verified English name | Shanghai Qing Ping Pharma Co., Ltd. romanized | Y20190006582 | A | Exact ingredient | 2026/01/31 | CDE |
| 盐酸多西环素 · No verified English name | Kun Shandong Fang Pharma Co., Ltd. romanized | Y20190006560 | A | Exact ingredient | — | CDE |
| 盐酸多西环素 · No verified English name | Shijiazhuang Hua Shu Shan He Pharma Co., Ltd. romanized | Y20190006021 | A | Exact ingredient | — | CDE |
| 盐酸多西环素 · No verified English name | Hebei Dong Feng Pharma Co., Ltd. romanized | Y20190005098 | A | Exact ingredient | 2025/02/09 | CDE |
| 盐酸多西环素 · No verified English name | Suzhou Di Wu Pharmaceutical Factory Co., Ltd. romanized | Y20190005068 | A | Exact ingredient | — | CDE |
| 盐酸多西环素 · No verified English name | Yan Cheng Su Hai Pharmaceutical Co., Ltd. romanized | Y20190004892 | A | Exact ingredient | 2025/07/18 | CDE |
| 盐酸多西环素 · No verified English name | Changzhou Pharmaceutical Factory Co., Ltd. romanized | Y20190004505 | A | Exact ingredient | 2025/07/09 | CDE |
| 盐酸多西环素 · No verified English name | Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | Y20190004072 | A | Exact ingredient | 2025/07/30 | CDE |
| 盐酸多西环素 · No verified English name | Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | Y20190002589 | A | Exact ingredient | 2024/09/11 | CDE |
| 盐酸多西环素 · No verified English name | Shandong Lukang Pharmaceutical Co.,Ltd. | Y20190002114 | A | Exact ingredient | 2025/01/23 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
CYHB2602003
Fact date: 2026/11/04 · Site observation date: 2026/11/05
View source ↗Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
US$200
Billed every month
Sign in to subscribeUS$540
Billed every three months
US$180 per month
Sign in to subscribeUS$1,920
Billed every year
US$160 per month
Sign in to subscribeSeparate one-time purchase
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy